Background: A large proportion of patients with type 2 diabetes mellitus have diabetic nephropathy. Despite current therapies including renin-angiotensin system inhibitors, diabetic nephropathy progresses to end-stage renal disease in most of these patients. Therefore, there is an urgent need to find new treatments for such patients. The aim of this study was to evaluate the efficacy of silymarin, an herbal drug with antioxidant and anti-inflammatory properties, in preventing the progression of diabetic nephropathy.
D
iabetic nephropathy is the most common cause of end-stage renal disease worldwide. 1 Activation of the renin-angiotensin system (RAS) has a major role in the pathogenesis of diabetic nephropathy. Inhibition of this system by angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) currently is the mainstay of diabetic nephropathy management. [2] [3] [4] However, despite RAS inhibition, diabetic nephropathy progresses to endstage renal disease in a large proportion of patients. 4 This shows that in addition to the RAS, other pathways are involved in the pathogenesis of diabetic nephropathy, and suggests that finding ways to block these pathways could lead to new treatments. 3, 5 Oxidative stress and inflammation are considered major alternative pathways contributing to the pathogenesis of diabetic nephropathy. 6, 7 Several studies to date have evaluated the efficacy of therapeutic agents that target these pathways, with some showing promising results. [5] [6] [7] However, the endeavor to find novel antioxidant and anti-inflammatory agents that arrest the progression of diabetic nephropathy while lacking major side effects continues.
Silymarin, the main active constituent in the seeds of Silybum marianum, or milk thistle, is a lipophilic extract comprising 3 isomeric flavonolignans (silybin, silydianin, and silychristin). 8 Of these, silybin has the highest level of activity and makes up 50%-60% of silymarin extract. 8 This herbal drug currently is produced by several pharmaceutical companies and is available in most countries around the world. Silymarin exerts potent antioxidant, anti-inflammatory, and antifibrotic properties and has been in use for treatment of several ailments, especially hepatobiliary diseases, since ancient times. 8 Silymarin has been shown to protect renal cells against nephrotoxic agents by hampering oxidative stress and inflammation and inducing renal cell proliferation and DNA and protein synthesis. [9] [10] [11] [12] Furthermore, recent preclinical studies have shown the efficacy of this medication in attenuating proteinuria and preventing the progression of diabetic nephropathy in animal models of diabetes. 13, 14 However, although this herbal medicine has a high safety profile and no major side effects, 8 no study of humans to date has to our knowledge evaluated the potential efficacy of silymarin in preventing the progression of diabetic nephropathy. Considering these facts, this trial was performed to evaluate the efficacy of the addition of silymarin to RAS inhibitors in reducing proteinuria in patients with type 2 diabetes with overt nephropathy. In order to delineate its possible mechanisms of action, the effects of silymarin on urinary and serum levels of tumor necrosis factor ␣ (TNF-␣), as an inflammatory marker; malondialdehyde (MDA), as an oxidative stress marker; and transforming growth factor ␤ (TGF␤), as a marker of fibrosis, also were evaluated.
METHODS

Study Design and Participants
This study was a randomized, double-blind, placebo-controlled, 2-arm parallel-group, phase 2 clinical trial and consisted of screening, run-in, and treatment phases. In the screening phase of the trial, all patients with type 2 diabetes aged 30-70 years who were under regular treatment at the Diabetes Clinic of Shiraz University of Medical Sciences were evaluated. They provided a medical history and underwent a complete physical examination; pertinent clinical laboratory parameters also were measured.
Participants were required to have: (1) overt proteinuria, defined as urinary albumin excretion Ͼ300 mg/24 h in 2 consecutive determinations separated by 2 weeks within a month before the enrollment despite treatment with the highest US Food and Drug Administration-recommended doses of an ACE inhibitor or ARB for at least 6 months; (2) treatment of hyperglycemia with (but not limited to) an oral hypoglycemic agent or insulin; in case of consumption of a thiazolidinedione, a stable dose had to be used for at least 6 months; (3) treatment of hypercholesterolemia with (but not limited to) a statin; and (4) presence of diabetic retinopathy.
Exclusion criteria were advanced chronic kidney disease, defined as estimated glomerular filtration rate (eGFR) Ͻ30 mL/min/ 1.73 m 2 ; severely uncontrolled diabetes, defined as hemoglobin A 1c (HbA 1c ) level Ͼ10%; uncontrolled hypertension, defined as systolic blood pressure (BP) Ͼ160 mm Hg or diastolic BP Ͼ100 mm Hg despite antihypertensive therapy; secondary forms of hypertension with defined cause other than diabetes mellitus; other kidney diseases; history of solid-organ transplant; chronic heart failure with New York Heart Association class III or IV; active infection; hepatitis virus or human immunodeficiency virus (HIV) infection; active malignancy; pregnancy; use of one of certain specified medications within 2 months prior to enrollment in the study (nonsteroidal anti-inflammatory agents and antioxidant supplements, including vitamin E, vitamin C, N-acetyl-cysteine, pentoxifylline, lipoic acid, fish oil extracts [omega-3 fatty acids], soy extracts [isoflavones], green tea preparations, pomegranate extracts, and grape extracts); history of drug or alcohol dependency or cigarette smoking; and psychiatric or neurologic condition preventing mindful consent to the study and/or adherence to the study protocol.
This study was reviewed and approved by the Ethical Committee of Shiraz University of Medical Sciences and performed in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines. All participants gave their informed written consent before enrollment in this study.
Study Protocol
Run-In
Patients who met all inclusion criteria and no exclusion criteria and were already consuming the highest recommended dose of an ACE inhibitor or ARB for a minimum of 6 months with optimal control of BP bypassed the run-in period and were authorized to proceed directly to determination of baseline parameters and then randomization. Patients who met the study criteria except for not receiving the maximum recommended dose of an ACE inhibitor or ARB or not receiving the adequate duration of antihypertensive background therapy were either switched to the highest recommended dose of their present ACE inhibitor or ARB or embarked on treatment with losartan, 100 mg/d, combined with non-ACE inhibitor/non-ARB antihypertensive medications for a maximum 6-month run-in period to attain optimal BP control. The goal BP was Յ130/80 mm Hg. Only patients with urinary albumin excretion Ͼ300 mg/24 h at the end of the run-in period were allowed to proceed to establishing baseline parameters followed by randomization.
Randomization and Treatment
Patients were randomly assigned to 2 equal groups to receive one 140-mg tablet of silymarin or 1 tablet of placebo 3 times a day for 3 months. This dosage was chosen because it has been shown to be safe and effective in the treatment of liver diseases. 8 Block randomization with fixed block size of 4 was done by an investigator who had no clinical involvement in the study according to a randomization sequence generated by Random Allocation Software (http://saghaei.net). 15 All drug and placebo tablets were made by Goldaru Pharmaceutical Laboratories (www.goldaru-co.com) and were supplied by the Shiraz School of Pharmacy in prepacked bottles numbered for each patient according to the randomization sequence. Each patient was given an order number and received the medications in the corresponding prepacked bottles. All drug and placebo tablets were similar in size, shape, weight, color, and taste. Clinical investigators, laboratory personnel, and patients were all masked to the treatment assignment. There were no changes in antihypertensive, antidiabetic, and antihyperlipidemic medications of patients throughout the treatment phase of the study.
Measurements
Patients were evaluated at baseline and then monthly after randomization. At each visit, office BP was measured by the same investigator using a mercury sphygmomanometer in a sitting position after 5 minutes of rest; 2 BP readings separated by 5 minutes were obtained and averaged for the BP of record. Patients were asked about experiencing adverse effects of therapy at each visit. Before each visit, fasting venous blood and first-morning urine samples were obtained from each patient. After collection, all serum and urinary samples were centrifuged at 3,000g for 10 minutes, aliquoted, and stored at Ϫ80°C until thawed and analyzed in a single batch. In order to decrease the variation in urinary albumin excretion, patients were instructed that their physical activities on each day prior to overnight urine sampling should be approximately similar and unusual changes in physical activity should be avoided. Urinary albumin-creatinine ratio (UACR) and serum creatinine and fasting plasma glucose were measured for all patients at each visit during the treatment phase of the study as part of their routine work-up. Furthermore, HbA 1c , lipid profile, and serum and urinary TNF-␣, MDA, and TGF␤ were measured at baseline and at the end of the treatment phase for all patients.
Urinary albumin was measured by nephelometry. Serum and urinary creatinine were measured by an autoanalyzer using the Jaffé method; lipid profiles also were measured by autoanalyzer. HbA 1c was measured by high-performance liquid chromatography. Serum and urinary TNF-␣ and TGF␤ were measured by ultrasensitive enzyme-linked immunosorbent assay kits (Invitrogen [www.invitrogen.com] for TNF-␣ and DRG [www.drgdiagnostics.de] for TGF␤). Intra-and interassay coefficients of variation were 5.9% and 8.5% and 1% and 7.5%, respectively. Serum and urinary MDA levels were determined using a thiobarbituric acid-based colorimetric assay and measuring absorbance at 532 nm (NWLSS Malondialdehyde Assay, www.nwlifescience. com). Intra-and interassay coefficients of variation were 4.5% and 5%, respectively. In order to compensate for variable urinary TNF-␣, TGF␤, and MDA levels, these levels were expressed as per concomitant urinary creatinine levels. eGFR was calculated using the 4-variable MDRD (Modification of Diet in Renal Disease) Study equation.
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Statistical Analysis
The primary efficacy parameter of this study was absolute change in UACR before and after the end of the treatment phase of the trial. In accordance with 2 other trials with similar designs performed on patients with diabetic nephropathy at our center, 17, 18 to detect a mean difference of 800 mg/g in absolute change in UACR between the 2 groups with standard deviation of 1,000 mg/g, 2-sided significance level of 5%, and power of 80%, a sample size of 25 patients per group was calculated. Considering a dropout rate of 20% postrandomization, a sample size of 30 patients per group was determined. Secondary outcome measures were number of patients with a Ͼ50% reduction in UACR at the end of the treatment phase and absolute changes in urinary and serum levels of TNF-␣, MDA, and TGF␤ and serum levels of creatinine, fasting plasma glucose, triglycerides, total cholesterol, low-(LDL) and high-density lipoprotein cholesterol, and HbA 1c and eGFR.
Statistical analyses were performed using the SPSS base 15 (SPSS Inc, www.ibm.com/software/analytics/spss/products/statistics) statistical software package. Baseline data with normal distribution were compared between the 2 groups using independent-samples t test. Baseline data with skewed distribution were compared using Mann-Whitney U test. Categorical data were compared using 2 or Fisher exact tests. Changes in measured parameters were calculated by subtracting baseline values at the onset of the treatment phase from corresponding values at the end of the treatment phase. Correlations were calculated by Spearman rank correlation. P Ͻ 0.05 was considered to be statistically significant.
RESULTS
The screening phase of the trial started in October 2010; the treatment phase was completed in November 2011. As shown in the flow diagram (Fig 1) , 60 patients were enrolled and randomly assigned to 2 equal groups to receive either silymarin or placebo. In the silymarin group, one patient died during the second week of the treatment phase due to myocardial infarction; she was a known case of coronary artery disease with previous myocardial infarction. Another patient from the silymarin group was detected to have high uncontrolled BP due to nonadherence to treatment with antihypertensive medications during the first monthly follow-up visit and was excluded from the study by the investigators. In the placebo group, 2 patients withdrew their consent and dropped out of the study during the first month of the treatment phase. Eventually, 28 patients in each group completed the 3-month treatment phase of the trial. As listed in Tables 1 and 2 , there were no statistically significant differences between the 2 groups in terms of baseline clinical characteristics and antihypertensive or antidiabetic medications of participants.
Changes in the measured parameters after the completion of the treatment phase are listed in Table  3 . Mean UACR levels decreased in both groups; however, this decrement was significantly higher in the silymarin group. Moreover, at the end of the treatment phase, UACR decreased Ͼ50% in 12 patients in the silymarin group compared with 6 patients in the placebo group (P ϭ 0.09).
As listed in Table 3 , at the end of the treatment phase, mean urinary and serum TNF-␣ levels decreased in both groups. Although these decrements were higher in the silymarin group, only the decrement in mean urinary TNF-␣ levels was significantly higher in the silymarin group compared with the placebo group. Moreover, mean urinary and serum MDA levels decreased significantly in the silymarin group compared with increasing values in the placebo group. Mean urinary TGF␤ levels decreased in both groups, whereas mean serum TGF␤ levels decreased in the silymarin group but increased in the placebo group. However, no statistically significant differences were found between the 2 groups in terms of these changes.
Mean values for changes in systolic and diastolic BPs, serum creatinine, fasting plasma glucose, triglycerides, total cholesterol, LDL and high-density lipoprotein cholesterol, HbA 1c , and eGFR values were not significantly different between the 2 groups.
Baseline UACRs in all enrolled patients were correlated significantly with baseline urinary TNF-␣ (r ϭ 0.45; P Ͻ 0.001) and TGF␤ (r ϭ 0.55; P Ͻ 0.001) levels. No significant correlations were found between baseline urinary and serum TNF-␣ levels. Likewise, no correlations were found between baseline urinary and serum TGF␤ levels or baseline urinary and serum MDA levels. Moreover, in the silymarin group, change in UACR was correlated significantly with change in urinary TNF-␣ (r ϭ 0.47; P ϭ 0.01) and change in urinary TGF␤ (r ϭ 0.46; P ϭ 0.02) levels. However, in the placebo group, no correlations were found between change in UACR and changes in urinary TNF-␣ and TGF␤ levels. Moreover, no correlations were found between changes in either systolic or diastolic BP and change in UACR in either group.
The frequency of serious and other adverse events in patients is listed in Table 4 . Other adverse events in both groups occurred in the first 2 weeks of treatment; none was sufficiently severe to cause patients to stop treatment.
DISCUSSION
To our knowledge our study is the first to demonstrate the efficacy and safety of adding silymarin to RAS inhibitors in reducing proteinuria in patients with type 2 diabetes with overt nephropathy. Inhibition of inflammatory mediators such as TNF-␣ and attenuation of oxidative stress may be the possible mechanisms behind this observed efficacy.
The pathogenesis of diabetic nephropathy is complex and not yet fully understood. Hemodynamic and metabolic derangements in diabetes, including chronic Assessed for eligibility (n=647) Excluded (n=364):
• Not meeting inclusion criteria (n=336) • Declined to participate (n=28)
Primary efficacy analysis (n=28)
Early termination (n=2):
• Death due to myocardial infarction (n=1)
• High uncontrolled blood pressure (n=1)
Silymarin (n=30)
• Withdrew their consent hyperglycemia and excessive production of advanced glycation end products, induce the production of reactive oxygen species and inflammatory mediators in the renal milieu and inhibit antioxidant defense mechanisms, resulting in kidney injury and eventually fibrosis. 6,7 TNF-␣ is one of the inflammatory cytokines proposed to have an important role in the pathogenesis of diabetic nephropathy. 6 Urinary and serum levels of this cytokine have been found to be higher in diabetic patients with diabetic nephropathy compared with healthy controls and diabetic patients without diabetic nephropathy. These levels have been shown to be correlated closely with levels of proteinuria, increasing with the progression of diabetic nephropathy. [19] [20] [21] Our study also showed a statistically significant positive correlation between baseline UACR and urinary TNF-␣ levels. Moreover, the reduction in urinary and serum TNF-␣ levels was greater in the silymarin group than in the placebo group. However, only the decrement in urinary TNF-␣ levels reached significance and the reduction in its serum levels was near significant. Several in vitro studies of animals and humans to date have reported the efficacy of silymarin in inhibiting TNF-␣ production in different cells and tissues, including renal tissue, and reducing serum levels of this cytokine, mainly through inhibition of the nuclear factor-B signaling pathway. 11, [22] [23] [24] [25] [26] [27] However, this is the first report of the efficacy of this drug in reducing urinary TNF-␣ levels. In addition, in our study, a significant correlation was found between changes in UACR and urinary TNF-␣ levels in silymarin-treated patients. Similar to our findings, other novel therapies such as pentoxifylline that have been shown to reduce proteinuria in patients with diabetic nephropathy have also reduced urinary TNF-␣ levels. Additionally, a significant positive correlation has been reported between changes in proteinuria and urinary levels of this cytokine in pentoxifyllinetreated patients.
28,29 Therefore, inhibition of TNF-␣ production may be a possible mechanism for the observed antiproteinuric effect of silymarin.
Urinary and serum levels of lipid peroxidation markers, including MDA, have been reported to be higher in diabetic patients with diabetic nephropathy compared with diabetic patients without diabetic nephropathy or healthy controls. [30] [31] [32] Furthermore, urinary and serum MDA levels have been shown to be correlated positively with degrees of glomerulosclero- Note: Continuous data are expressed as mean Ϯ standard deviation; categorical data are expressed as number (percentage). Conversion factors for units: SCr in mg/dL to mol/L, ϫ88.4; eGFR in mL/min/1.73 m 2 to mL/s/1.73 m 2 , ϫ0.01667; serum TG in mg/dL to mmol/L, ϫ0.01129; serum TC, LDL-C, and HDL-C in mg/dL to mmol/L, ϫ0.02586.
Abbreviations: BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; HbA 1c , hemoglobin A 1c ; HTN, hypertension; LDL-C, low-density lipoprotein-cholesterol; MDA, malondialdehyde; MI, myocardial infarction; PCTA, percutaneous transluminal coronary angioplasty; SCr, serum creatinine; TC, total cholesterol; TG, triglycerides; TGF␤, transforming growth factor ␤; TNF-␣, tumor necrosis factor ␣; UACR, urinary albumin-creatinine ratio. sis and proteinuria in patients with diabetic nephropathy, respectively. 30, 32 In our study, baseline UACRs were not correlated with baseline urinary or serum MDA levels. The same was true about lack of correlations between changes in UACR and urinary or serum levels of this marker. These findings may be explained by a small sample size and hence the low power of this study to detect these correlations. However, compared with placebo, silymarin therapy significantly reduced urinary and serum MDA levels. In support of our findings, silymarin therapy in cirrhotic patients with diabetes has been reported to significantly reduce serum MDA levels compared with placebo. 33 Moreover, in preclinical studies that have shown the efficacy of silymarin in the prevention of diabetic nephropathy in diabetic animals, silymarin reduces oxidative stress markers and restores antioxidant enzymes. 13, 14 Furthermore, silymarin has been shown to inhibit the formation and deposition of advanced glycation end products in glomeruli of diabetic rats. 27 Therefore, inhibition of oxidative stress-induced kidney injury may be another explanation for the observed efficacy of silymarin in alleviating proteinuria in patients with diabetic nephropathy.
TGF␤ is another cytokine that has a major role in the pathogenesis of diabetic nephropathy by mediating glomerulosclerosis and tubulointerstitial fibrosis. 3, 5 Its urinary and serum levels have been shown to be elevated in patients with diabetic nephropathy and to have positive correlations with degree of proteinuria and progression of diabetic nephropathy. [34] [35] [36] Furthermore, some novel therapies that have been reported to reduce proteinuria in diabetic nephropathy have also reduced levels of this cytokine. 17, 37 In our study, positive correlations were found between baseline UACR and urinary TGF␤ levels. Moreover, changes in these parameters were also correlated positively in silymarin-treated patients. Preclinical studies have also reported the anti-TGF␤ and antifibrotic effects of silymarin. 38, 39 However, despite the higher reduction in urinary and serum levels of TGF␤ Abbreviations: ⌬, change; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA 1c , hemoglobin A 1c ; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein-cholesterol; MDA, malondialdehyde; SCr, serum creatinine; TC, total cholesterol; TG, triglyceride; TGF␤, transforming growth factor ␤; TNF-␣, tumor necrosis factor ␣; UACR, urinary albumincreatinine ratio. in the silymarin group compared with the placebo group, none of these changes reached statistical significance. Evaluation of the effects of silymarin on TGF␤ demands further studies with larger sample sizes and longer durations.
Similar to the studies by Navarro et al, 21 ,28 in our study, no significant correlations were found between urinary and serum TNF-␣ levels. The same was true about lack of correlations between urinary and serum TGF␤ levels and also MDA. Although these findings may be due to the small sample size and therefore low power of our study to detect such correlations, it also may point to the possible intrarenal production of these compounds. 28 In our study, there were no differences between the silymarin and placebo groups in terms of changes in systolic and diastolic BP, fasting plasma glucose, HbA 1c , triglycerides, total cholesterol, and LDL and high-density lipoprotein cholesterol levels. Therefore, the higher reduction in proteinuria in the silymarin group probably is not due to better hemodynamic or metabolic control in these patients. There are reports of the efficacy of adding silymarin to standard therapy in reducing blood glucose, HbA 1c , triglyceride, total cholesterol, and LDL cholesterol levels in patients with diabetes. However, these changes were evident after at least 4 months of silymarin therapy.
33,40,41
Although we did not observe these metabolic effects in our study, they may become evident in future trials with longer durations.
Death due to myocardial infarction in one of the patients in the silymarin group most probably was due to her underlying coronary artery disease. Except for the gastrointestinal disturbances and headache in a few patients, silymarin was found to be safe and without major side effects. However, the safety of silymarin therapy in patients with diabetic nephropathy should be evaluated further in larger trials with longer durations.
The main limitations to our study and interpretation of its results are the small sample size and short duration of the treatment phase. Moreover, in addition to proteinuria, future studies should consider other outcome measures, such as time to renal replacement therapy.
In conclusion, to our knowledge, this is the first randomized, double-blind, placebo-controlled, clinical trial that demonstrates the possible efficacy and safety of silymarin addition to RAS inhibitors in attenuating proteinuria in patients with type 2 diabetes with overt nephropathy. This observed efficacy may be due to the anti-inflammatory and antioxidative properties of silymarin. Future multicenter randomized trials with larger sample sizes and longer durations of treatment are necessary to further ascertain the long-term efficacy and safety of adding silymarin to RAS inhibitors in reducing the progression of diabetic nephropathy and to elucidate its mechanisms of action.
